Significant regulatory developments include the FDA approval of Eisai-Biogen’s subcutaneous Leqembi formulation and the recent resignations of three CDC leaders amid policy disagreements with the Trump administration. Concurrently, policy shifts signal potential impacts on biotech tech transfer frameworks and drug price negotiations under the Inflation Reduction Act, with implications for industry innovation, market dynamics, and public health policy execution.